Results 281 to 290 of about 15,170,590 (380)

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Maternal Bacillus probiotic regulates offspring growth and immunity via spleen IGF-1/mTOR and FOXO1/IL-10 pathways. [PDF]

open access: yesSci Rep
Aldayel TS   +6 more
europepmc   +1 more source

Expression analysis of IL-10 and IFN-γ genes in head kidney of Catla catla (Ham.) fed with Limonia acidissima L [PDF]

open access: green, 2015
Srinivasan Ponnuraj   +3 more
openalex  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

IL-10 Plays a Critical Role in Mitigating Acute Anaemia Development During African Trypanosome Infection. [PDF]

open access: yesPathogens
Živalj M   +9 more
europepmc   +1 more source

Lack of effects of the TNF-α and IL-10 gene polymorphisms in Mexican patients with lepromatous leprosy

open access: diamond, 2012
Jesús Salvador Velarde‐Félix   +5 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy